カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のグルカゴン様ペプチド-2（GLP-2）アゴニスト市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Glucagon-like Peptide-2 (GLP-2) Agonist Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19354）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19354
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：71
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のグルカゴン様ペプチド-2（GLP-2）アゴニスト市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

グルカゴン様ペプチド-2（GLP-2）アゴニスト市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のグルカゴン様ペプチド-2（GLP-2）アゴニストの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

グルカゴン様ペプチド-2（GLP-2）アゴニスト市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・ガテックス、リベスティブ

用途別セグメントは次のように区分されます。
・病院、薬局、その他

世界のグルカゴン様ペプチド-2（GLP-2）アゴニスト市場の主要な市場プレーヤーは以下のとおりです。
・Takeda Pharmaceuticals

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、グルカゴン様ペプチド-2（GLP-2）アゴニスト製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なグルカゴン様ペプチド-2（GLP-2）アゴニストメーカーの企業概要、2019年～2022年までのグルカゴン様ペプチド-2（GLP-2）アゴニストの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なグルカゴン様ペプチド-2（GLP-2）アゴニストメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別グルカゴン様ペプチド-2（GLP-2）アゴニストの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのグルカゴン様ペプチド-2（GLP-2）アゴニストの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのグルカゴン様ペプチド-2（GLP-2）アゴニスト市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびグルカゴン様ペプチド-2（GLP-2）アゴニストの産業チェーンを掲載しています。
・第13、14、15章では、グルカゴン様ペプチド-2（GLP-2）アゴニストの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- グルカゴン様ペプチド-2（GLP-2）アゴニストの概要
- 種類別分析（2017年vs2021年vs2028年）：ガテックス、リベスティブ
- 用途別分析（2017年vs2021年vs2028年）：病院、薬局、その他
- 世界のグルカゴン様ペプチド-2（GLP-2）アゴニスト市場規模・予測
- 世界のグルカゴン様ペプチド-2（GLP-2）アゴニスト生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- Takeda Pharmaceuticals
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：ガテックス、リベスティブ
・用途別分析2017年-2028年：病院、薬局、その他
・グルカゴン様ペプチド-2（GLP-2）アゴニストの北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・グルカゴン様ペプチド-2（GLP-2）アゴニストのヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・グルカゴン様ペプチド-2（GLP-2）アゴニストのアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・グルカゴン様ペプチド-2（GLP-2）アゴニストの南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・グルカゴン様ペプチド-2（GLP-2）アゴニストの中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Glucagon-like Peptide-2 (GLP-2) Agonist market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Glucagon-like Peptide-2 (GLP-2) Agonist market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Glucagon-like Peptide-2 (GLP-2) Agonist global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Gattex segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist include Takeda Pharmaceuticals, , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Glucagon-like Peptide-2 (GLP-2) Agonist market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Gattex
Revestive
Market segment by Application can be divided into
Hospital
Pharmacy
Other
The key market players for global Glucagon-like Peptide-2 (GLP-2) Agonist market are listed below:
Takeda Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Glucagon-like Peptide-2 (GLP-2) Agonist product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist, with price, sales, revenue and global market share of Glucagon-like Peptide-2 (GLP-2) Agonist from 2019 to 2022.
Chapter 3, the Glucagon-like Peptide-2 (GLP-2) Agonist competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Glucagon-like Peptide-2 (GLP-2) Agonist breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Glucagon-like Peptide-2 (GLP-2) Agonist market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Glucagon-like Peptide-2 (GLP-2) Agonist.
Chapter 13, 14, and 15, to describe Glucagon-like Peptide-2 (GLP-2) Agonist sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Glucagon-like Peptide-2 (GLP-2) Agonist Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Gattex
1.2.3 Revestive
1.3 Market Analysis by Application
1.3.1 Overview: Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size & Forecast
1.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume (2017-2028)
1.4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (2017-2028)
1.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Production Capacity Analysis
1.5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Total Production Capacity (2017-2028)
1.5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
1.6.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
1.6.3 Glucagon-like Peptide-2 (GLP-2) Agonist Trends Analysis
2 Manufacturers Profiles
2.1 Takeda Pharmaceuticals
2.1.1 Takeda Pharmaceuticals Details
2.1.2 Takeda Pharmaceuticals Major Business
2.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product and Services
2.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Glucagon-like Peptide-2 (GLP-2) Agonist Breakdown Data by Manufacturer
3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Glucagon-like Peptide-2 (GLP-2) Agonist
3.4 Market Concentration Rate
3.4.1 Top 3 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer Market Share in 2021
3.4.2 Top 6 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer Market Share in 2021
3.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Glucagon-like Peptide-2 (GLP-2) Agonist Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region
4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Region (2017-2028)
4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2017-2028)
4.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028)
4.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028)
4.4 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028)
4.5 South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028)
4.6 Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Type (2017-2028)
5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2017-2028)
5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Application (2017-2028)
6.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2017-2028)
6.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2028)
7.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2028)
7.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
7.3.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Country (2017-2028)
7.3.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2028)
8.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2028)
8.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
8.3.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Country (2017-2028)
8.3.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2028)
9.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2028)
9.3 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Region
9.3.1 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2028)
10.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2028)
10.3 South America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
10.3.1 South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Country (2017-2028)
10.3.2 South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2028)
11.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2028)
11.3 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
11.3.1 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Glucagon-like Peptide-2 (GLP-2) Agonist and Key Manufacturers
12.2 Manufacturing Costs Percentage of Glucagon-like Peptide-2 (GLP-2) Agonist
12.3 Glucagon-like Peptide-2 (GLP-2) Agonist Production Process
12.4 Glucagon-like Peptide-2 (GLP-2) Agonist Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Glucagon-like Peptide-2 (GLP-2) Agonist Typical Distributors
13.3 Glucagon-like Peptide-2 (GLP-2) Agonist Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Takeda Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 4. Takeda Pharmaceuticals Major Business
Table 5. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product and Services
Table 6. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 8. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Glucagon-like Peptide-2 (GLP-2) Agonist, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Production Capacity by Company, (K Units): 2020 VS 2021
Table 11. Head Office and Glucagon-like Peptide-2 (GLP-2) Agonist Production Site of Key Manufacturer
Table 12. Glucagon-like Peptide-2 (GLP-2) Agonist New Entrant and Capacity Expansion Plans
Table 13. Glucagon-like Peptide-2 (GLP-2) Agonist Mergers & Acquisitions in the Past Five Years
Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2017-2022) & (K Units)
Table 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2023-2028) & (K Units)
Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2022) & (K Units)
Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2023-2028) & (K Units)
Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2017-2022) & (USD/Unit)
Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2023-2028) & (USD/Unit)
Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2022) & (K Units)
Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2023-2028) & (K Units)
Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2017-2022) & (USD/Unit)
Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2023-2028) & (USD/Unit)
Table 30. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2017-2022) & (K Units)
Table 31. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2023-2028) & (K Units)
Table 32. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2022) & (K Units)
Table 35. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2023-2028) & (K Units)
Table 36. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2022) & (K Units)
Table 37. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2023-2028) & (K Units)
Table 38. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2017-2022) & (K Units)
Table 39. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2023-2028) & (K Units)
Table 40. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2022) & (K Units)
Table 43. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2023-2028) & (K Units)
Table 44. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2022) & (K Units)
Table 45. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2023-2028) & (K Units)
Table 46. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2017-2022) & (K Units)
Table 47. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2023-2028) & (K Units)
Table 48. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2022) & (K Units)
Table 51. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2023-2028) & (K Units)
Table 52. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2022) & (K Units)
Table 53. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2023-2028) & (K Units)
Table 54. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2017-2022) & (K Units)
Table 55. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2023-2028) & (K Units)
Table 56. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2022) & (K Units)
Table 59. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2023-2028) & (K Units)
Table 60. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2022) & (K Units)
Table 61. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2023-2028) & (K Units)
Table 62. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2017-2022) & (K Units)
Table 63. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2023-2028) & (K Units)
Table 64. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2017-2022) & (K Units)
Table 67. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2023-2028) & (K Units)
Table 68. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2017-2022) & (K Units)
Table 69. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2023-2028) & (K Units)
Table 70. Glucagon-like Peptide-2 (GLP-2) Agonist Raw Material
Table 71. Key Manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Glucagon-like Peptide-2 (GLP-2) Agonist Typical Distributors
Table 75. Glucagon-like Peptide-2 (GLP-2) Agonist Typical Customers
List of Figures
Figure 1. Glucagon-like Peptide-2 (GLP-2) Agonist Picture
Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type in 2021
Figure 3. Gattex
Figure 4. Revestive
Figure 5. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Pharmacy
Figure 8. Other
Figure 9. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 10. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2017-2028) & (K Units)
Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price (2017-2028) & (USD/Unit)
Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Production Capacity (2017-2028) & (K Units)
Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Production Capacity by Geographic Region: 2022 VS 2028
Figure 15. Glucagon-like Peptide-2 (GLP-2) Agonist Market Drivers
Figure 16. Glucagon-like Peptide-2 (GLP-2) Agonist Market Restraints
Figure 17. Glucagon-like Peptide-2 (GLP-2) Agonist Market Trends
Figure 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturer in 2021
Figure 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Manufacturer in 2021
Figure 20. Glucagon-like Peptide-2 (GLP-2) Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 21. Top 3 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer (Revenue) Market Share in 2021
Figure 22. Top 6 Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturer (Revenue) Market Share in 2021
Figure 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2017-2028)
Figure 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2017-2028)
Figure 25. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028) & (USD Million)
Figure 26. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028) & (USD Million)
Figure 27. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028) & (USD Million)
Figure 28. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028) & (USD Million)
Figure 29. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2017-2028) & (USD Million)
Figure 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2017-2028)
Figure 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2017-2028)
Figure 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2017-2028) & (USD/Unit)
Figure 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2017-2028)
Figure 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2017-2028)
Figure 35. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2017-2028) & (USD/Unit)
Figure 36. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2017-2028)
Figure 37. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2017-2028)
Figure 38. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2017-2028)
Figure 39. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2017-2028)
Figure 40. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2017-2028)
Figure 44. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2017-2028)
Figure 45. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2017-2028)
Figure 46. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2017-2028)
Figure 47. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. United Kingdom Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Russia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2017-2028)
Figure 53. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2017-2028)
Figure 54. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2017-2028)
Figure 56. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2017-2028)
Figure 63. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2017-2028)
Figure 64. South America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Country (2017-2028)
Figure 65. South America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Country (2017-2028)
Figure 66. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2017-2028)
Figure 69. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2017-2028)
Figure 70. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2017-2028)
Figure 71. Middle East & Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2017-2028)
Figure 72. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. South Africa Glucagon-like Peptide-2 (GLP-2) Agonist Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Manufacturing Cost Structure Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist in 2021
Figure 77. Manufacturing Process Analysis of Glucagon-like Peptide-2 (GLP-2) Agonist
Figure 78. Glucagon-like Peptide-2 (GLP-2) Agonist Industrial Chain
Figure 79. Sales Channel: Direct Channel vs Indirect Channel
Figure 80. Methodology
Figure 81. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界の抗糖尿病グルカゴン様ペプチド1アゴニスト市場2022年：市場規模予測（～2028年）
  • 世界のトロンボポエチン受容体アゴニスト市場2022年：市場規模予測（～2028年）
  • 世界のプロゲステロン受容体アゴニスト市場2022年：市場規模予測（～2028年）
  • 世界の自動ペプチド連続合成装置市場2022年：市場規模予測（～2028年）
  • 世界のゼラチンペプチド血漿代替品市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19354 )"世界のグルカゴン様ペプチド-2（GLP-2）アゴニスト市場2022年：市場規模予測（～2028年）" (英文：Global Glucagon-like Peptide-2 (GLP-2) Agonist Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。